Search research articles
Contact Us
Filters
Showing results (341-350 of 361) with videos related to
Page
of 37
Sort By:
JTO Clinical and Research Reports
|
August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
William Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
Lancet (London, England)
|
June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
JTO Clinical and Research Reports
|
January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis
Margaret Stalker, Connor B Grady, Alex Watts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
F Griesinger, G Curigliano, M Thomas, et al.
Cancer Cell
|
February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Adam Barsouk, Omar Elghawy, Alex Watts, et al.
Scientific Reports
|
July 2, 2025
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
J Abraham, V Domenyuk, N Perdigones, et al.
JCO Precision Oncology
|
December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions
Tejas Patil, Jessica J Lin, Parneet K Cheema, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Scott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
Page
of 37
Search research articles
Search
Showing results (341-350 of 361) with videos related to
Sort By:
Page
of 37
JTO Clinical and Research Reports
|
August 19, 2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC
William Tompkins, Connor B Grady, Wei-Ting Hwang, et al.
Lancet (London, England)
|
June 5, 2025
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, et al.
JTO Clinical and Research Reports
|
January 6, 2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis
Margaret Stalker, Connor B Grady, Alex Watts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 16, 2022
Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial
F Griesinger, G Curigliano, M Thomas, et al.
Cancer Cell
|
February 17, 2024
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
Barzin Y Nabet, Habib Hamidi, Myung Chang Lee, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2025
Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis
Adam Barsouk, Omar Elghawy, Alex Watts, et al.
Scientific Reports
|
July 2, 2025
Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors
J Abraham, V Domenyuk, N Perdigones, et al.
JCO Precision Oncology
|
December 22, 2025
CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (<i>NRG1</i>) Fusions
Tejas Patil, Jessica J Lin, Parneet K Cheema, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2019
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Scott J Antonia, Ani Balmanoukian, Julie Brahmer, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 23, 2023
Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)
Laura Burns, Chih-Yuan Hsu, Jennifer G Whisenant, et al.
Page
of 37